The new journal.

In line with EMBO’s reputation for promoting the most effective in the molecular existence sciences, a renowned band of senior editors and an equally well respected advisory table assure published content of the best scientific quality following rapid, rigorous and transparent peer review. EMBO Molecular Medicine offers a unique possibility to broadly distribute new findings in biomedical analysis and to improve links between clinicians and molecular biologists, said Hermann Bujard, EMBO Director. We wish that released papers will result in advances that will enhance the detection, diagnosis and clinical administration of diseases.In addition, our findings show that in patients with acute coronary syndromes treated with clopidogrel, the same variants in CYP2C19 were connected with adverse clinical outcomes, including a rate of death from cardiovascular causes, myocardial infarction, or stroke that was more than 50 percent better and an interest rate of stent thrombosis that was greater by one factor of three compared to the rate in noncarriers. There are compelling biologic data to aid these findings.